Workflow
心律失常管理解决方案
icon
Search documents
港股异动 | 微创医疗(00853)涨近5% 近日宣布重组心律管理业务 美银料其有望明年上半年...
Xin Lang Cai Jing· 2025-10-03 05:58
消息面上,微创医疗近日宣布重组心律管理业务。附属微创心通拟合并CRM Cayman。完成合并后, CRM Cayman将成为微创心通的全资附属,其主要从事心律管理业务,专注于心律失常管理解决方案, 其交易前股权价值为6.8亿美元。目前,微创医疗持有心通医疗46.12%;并持有CRM Cayman 50.13%权 益。 摩通大根认为,公司已就将其心律管理业务(CRM)与心通医疗合并达成最终协议。该行认为交易顺利完 成,有助消除持续困扰公司的重大不明朗因素。美银证券指出,公司引入国企背景的上海实业作为战略 股东,将支持财务与业务发展。该行预期,通过成本控制与处置非核心资产,公司有望于2026年上半年 实现盈利。另外,海外业务快速增长,亦可分散国内市场风险,并提供长远增长能见度。 来源:智通财经网 微创医疗(00853)涨近5%,截至发稿,涨4.74%,报14.36港元,成交额7918.4万港元。 ...
微创医疗涨近5% 近日宣布重组心律管理业务 美银料其有望明年上半年实现盈利
Zhi Tong Cai Jing· 2025-10-03 05:48
Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]
心通医疗宣布收购微创心律管理100%股权 标的公司估值为6.8亿美元
Core Viewpoint - The announcement highlights the agreement between HeartLink Medical and MicroPort Cardiac Rhythm Management for a business integration, aiming to enhance their strategic positioning in the global cardiovascular market [1][2]. Group 1: Transaction Details - HeartLink Medical plans to acquire 100% of MicroPort Cardiac Rhythm Management for a valuation of $680 million, through a directed share issuance at a price of HKD 1.35 per share [1]. - The acquisition will be executed by issuing new shares to existing shareholders of MicroPort Cardiac Rhythm Management, including its parent company MicroPort Medical and investment firms such as Hillhouse Capital and Yunfeng Capital [1]. Group 2: Business Integration and Strategic Goals - The integration aims to combine the core businesses of cardiac rhythm management and structural heart disease, creating a more comprehensive cardiovascular treatment solution [2]. - The transaction is expected to generate synergies that will diversify and enhance HeartLink Medical's existing business, particularly in structural heart disease and CRM solutions, while improving R&D capabilities, production capacity, distribution channels, and market expansion [1][2]. Group 3: Conditions for Completion - The final implementation of the integration is subject to several closing conditions, including approval from HeartLink Medical's independent shareholders [3].
微创系集体上涨 微创医疗宣布重组心律管理业务 打造心脏病综合解决方案平台
Zhi Tong Cai Jing· 2025-09-30 01:59
Core Viewpoint - The stocks of the MicroPort group have collectively risen, driven by the announcement of a restructuring in the cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with a subsidiary, MicroPort HeartLink, planning to merge with CRM Cayman [1] - Post-merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on solutions for arrhythmia management, with a pre-transaction equity value of USD 680 million [1] - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] Group 3: Strategic Intent - The restructuring is seen as a strategy to mitigate the pressure of meeting the "qualified listing" requirements for the cardiac rhythm management business [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - An agreement was made that if CRM does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]
心通医疗-B(02160)、合并附属公司及微创心律管理就交易订立合并协议
智通财经网· 2025-09-29 15:39
Group 1 - The company, HeartLink Medical-B (02160), announced a merger agreement with MicroPort CardioFlow CRM Limited and the target company, MicroPort Medical (00853), to acquire the target company for a valuation of $680 million [1] - The merger will result in the target company becoming an indirect wholly-owned subsidiary of HeartLink Medical, with its financial performance being consolidated into the group's financial results [1] - The target company specializes in CRM solutions, providing devices to monitor cardiac information and manage arrhythmias, including treatments for bradycardia and tachyarrhythmias [1] Group 2 - The board believes the transaction aligns with the group's strategic development, aiming to establish a globally influential cardiac product platform with a diversified product line [2] - The synergies generated from the transaction are expected to enhance and diversify the existing business, particularly strengthening the group's offerings in structural heart disease and CRM solutions [2] - The merger is anticipated to improve the company's R&D capabilities, production capacity, distribution channels, and market expansion efforts [2]
微创医疗(00853) - 自愿公告 - 有关拟进行心律管理业务之策略性重组而订立合併协议
2025-09-29 14:54
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* (於開曼群島註冊成立的有限公司) (股份代號:00853) 自願公告 有關擬進行心律管理業務之策略性重組而訂立合併協議 茲提述微創醫療科學有限公司(「本公司」,連同其附屬公司統稱為「本集團」)日期為二零二五年七月 十六日的公告(「該公告」),內容有關本集團心律管理業務之擬議重組。除非文義另有所指外,本公 告所用詞彙與該公告所界定者具有相同涵義。 本公司董事會(「董事會」)欣然宣佈,於二零二五年九月二十九日,CRM Cayman、微創心通及 MicroPort CardioFlow CRM Limited(「合併附屬公司」)訂立了一份合併協議(「合併協議」)。合併附屬 公司為一間於開曼群島註冊成立的獲豁免有限公司,並為微創心通間接全資擁有之附屬公司。 根據合併協議,微創心通將透過合併附屬公司以合併方式收購CRM Cayman。於該合併生效時, CRM Cayman將成為微創心通之間 ...